S&P 500   5,098.57 (-0.63%)
DOW   38,816.90 (-0.44%)
QQQ   438.58 (-1.23%)
AAPL   170.43 (-2.67%)
MSFT   406.75 (-1.97%)
META   493.74 (-0.89%)
GOOGL   132.07 (-0.96%)
AMZN   175.79 (-1.01%)
TSLA   183.57 (-2.43%)
NVDA   853.79 (+0.17%)
NIO   5.38 (+0.94%)
AMD   203.78 (-0.77%)
BABA   72.16 (+0.22%)
T   17.19 (+2.32%)
F   12.69 (-0.39%)
MU   94.96 (-0.85%)
CGC   2.92 (-3.31%)
GE   162.06 (+0.65%)
DIS   113.13 (-0.49%)
AMC   4.28 (-0.93%)
PFE   25.72 (-0.66%)
PYPL   59.90 (-0.13%)
XOM   105.30 (+0.90%)
S&P 500   5,098.57 (-0.63%)
DOW   38,816.90 (-0.44%)
QQQ   438.58 (-1.23%)
AAPL   170.43 (-2.67%)
MSFT   406.75 (-1.97%)
META   493.74 (-0.89%)
GOOGL   132.07 (-0.96%)
AMZN   175.79 (-1.01%)
TSLA   183.57 (-2.43%)
NVDA   853.79 (+0.17%)
NIO   5.38 (+0.94%)
AMD   203.78 (-0.77%)
BABA   72.16 (+0.22%)
T   17.19 (+2.32%)
F   12.69 (-0.39%)
MU   94.96 (-0.85%)
CGC   2.92 (-3.31%)
GE   162.06 (+0.65%)
DIS   113.13 (-0.49%)
AMC   4.28 (-0.93%)
PFE   25.72 (-0.66%)
PYPL   59.90 (-0.13%)
XOM   105.30 (+0.90%)
S&P 500   5,098.57 (-0.63%)
DOW   38,816.90 (-0.44%)
QQQ   438.58 (-1.23%)
AAPL   170.43 (-2.67%)
MSFT   406.75 (-1.97%)
META   493.74 (-0.89%)
GOOGL   132.07 (-0.96%)
AMZN   175.79 (-1.01%)
TSLA   183.57 (-2.43%)
NVDA   853.79 (+0.17%)
NIO   5.38 (+0.94%)
AMD   203.78 (-0.77%)
BABA   72.16 (+0.22%)
T   17.19 (+2.32%)
F   12.69 (-0.39%)
MU   94.96 (-0.85%)
CGC   2.92 (-3.31%)
GE   162.06 (+0.65%)
DIS   113.13 (-0.49%)
AMC   4.28 (-0.93%)
PFE   25.72 (-0.66%)
PYPL   59.90 (-0.13%)
XOM   105.30 (+0.90%)
S&P 500   5,098.57 (-0.63%)
DOW   38,816.90 (-0.44%)
QQQ   438.58 (-1.23%)
AAPL   170.43 (-2.67%)
MSFT   406.75 (-1.97%)
META   493.74 (-0.89%)
GOOGL   132.07 (-0.96%)
AMZN   175.79 (-1.01%)
TSLA   183.57 (-2.43%)
NVDA   853.79 (+0.17%)
NIO   5.38 (+0.94%)
AMD   203.78 (-0.77%)
BABA   72.16 (+0.22%)
T   17.19 (+2.32%)
F   12.69 (-0.39%)
MU   94.96 (-0.85%)
CGC   2.92 (-3.31%)
GE   162.06 (+0.65%)
DIS   113.13 (-0.49%)
AMC   4.28 (-0.93%)
PFE   25.72 (-0.66%)
PYPL   59.90 (-0.13%)
XOM   105.30 (+0.90%)
LON:VRP

Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis

GBX 55
+3.00 (+5.77%)
(As of 10/29/2020)
Today's Range
50
56
50-Day Range
55
55
52-Week Range
28.60
115
Volume
70,791 shs
Average Volume
150,610 shs
Market Capitalization
£228.00 million
Assets Under Management
N/A
Dividend Yield
N/A
Net Expense Ratio
0.00%
VRP stock logo

About Verona Pharma plc (VRP.L) (LON:VRP)

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

VRP Stock Price History

VRP ETF News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Michael Austwick Joins Verona Pharma as Non-Executive Director
BTIG Keeps Their Buy Rating on Verona Pharma (VRNA)
BTIG Reaffirms Their Buy Rating on Verona Pharma (VRNA)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
See More Headlines
Receive VRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter.

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Verona Pharma plc (VRP.L) (VRP)

Key Executives

  • Dr. Jan-Anders Karlsson (Age 64)
    CEO & Exec. Director
  • Mr. Piers John Morgan (Age 53)
    Chief Financial Officer
  • Ms. Claire Louise Poll L.C.S.W. (Age 52)
    B.A., B Juris, LLB, ASIA, Gen. Counsel
  • Ms. Victoria Stewart
    Director of Communications
  • Dr. Peter Spargo (Age 57)
    Sr. VP of Chemistry Manufacturing & Controls














VRP ETF - Frequently Asked Questions

How have VRP shares performed in 2024?

Verona Pharma plc (VRP.L)'s stock was trading at GBX 55 at the beginning of 2024. Since then, VRP shares have increased by 0.0% and is now trading at GBX 55.
View the best growth stocks for 2024 here
.

How were Verona Pharma plc (VRP.L)'s earnings last quarter?

Verona Pharma plc (VRP.L) (LON:VRP) announced its quarterly earnings results on Thursday, February, 27th. The company reported ($30.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($30.80) by $0.50.

What other stocks do shareholders of Verona Pharma plc (VRP.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Grifols (GRFS) and Innoviva (INVA).

How do I buy shares of Verona Pharma plc (VRP.L)?

Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:VRP) was last updated on 3/5/2024 by MarketBeat.com Staff